Modality
Fusion Protein
MOA
TYK2i
Target
TROP-2
Pathway
Angiogenesis
GISTCRC
Development Pipeline
Preclinical
~Jun 2023
→ ~Sep 2024
Phase 1
Dec 2024
→ Feb 2027
Phase 1Current
NCT06625129
259 pts·CRC
2024-12→2027-02·Completed
259 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-215mo awayConference· GIST
2027-02-0910mo awayInterim· CRC
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027
P1
Complet…
Catalysts
Conference
2026-08-21 · 5mo away
GIST
Interim
2027-02-09 · 10mo away
CRC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06625129 | Phase 1 | CRC | Completed | 259 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |